BioFocus DPI, Galapagos NV's service division, has added structural biology to its pre-clinical drug discovery services following the acquisition of Sareum Holdings by Galapagos.
This means that BioFocus now offers a range of lead optimisation services covering structural biology, biological screening, medicinal chemistry and ADME.
Sareum's X-ray crystallography platform enables the interactions between small molecules and the drug target to be studied at the atomic level and so aid the optimisation of the molecules into drugs.
Galapagos has acquired all of Sareum's service contracts relating to structure-based drug discovery, including the Crystal Bank (a collection of protein targets, available for rapid drug/protein structural analysis), a fragment screening library and specialised equipment for structure-based drug discovery.
